Implantable Ocular Drug Delivery Systems Segment to Grow at Highest CAGR During 2021–2028
According to our new market research study on “Ocular Drug Delivery Market to 2028 – Global Analysis and Forecast – by Technology, Formulation Type, Disease Type, and End User,” the market is expected to reach US$ 27,016.20 million by 2028 from US$ 16,404.32 million in 2021; it is expected to grow at a CAGR of 7.4% from 2021 to 2028. The report highlights trends prevailing in the market and drivers and hindrances pertaining to the market growth.
Based on technology, the ocular drug delivery market is segmented into implantable ocular drug delivery systems, particulate drug delivery systems, nanoparticle drug delivery system, and others. The implantable ocular drug delivery systems segment would account for the largest market share in 2021. The same segment is anticipated to register the highest CAGR in the market during the forecast period.
Based on formulation type, the ocular drug delivery market is segmented into liposomes and nanoparticles, solution, emulsion, suspension, and ointment. The solution segment would hold the largest share of the market in 2021, and it is estimated to register the highest CAGR in the market during 2021–2028. The growth of the solution segment is attributed to the increasing adoption of ocular drug delivery systems in solution forms, like eye drops and injectables.
Based on disease type, the ocular drug delivery market is segmented into glaucoma, diabetic retinopathy, dry eye syndrome, macular degeneration, cataract, diabetic macular edema, and others. The cataract segment would account for the largest market share in 2021. The market for this segment is estimated to grow at the highest CAGR from 2021 to 2028.
Based on end user, the ocular drug delivery market is segmented into hospitals, ophthalmic clinics, and ambulatory surgical centers. The hospitals segment would hold the largest share of the market in 2021, while the ophthalmic clinics segment is further estimated to register the highest CAGR in the market during the forecast period.
The COVID-19 pandemic has become the most significant challenge across the world. As this pandemic has stressed healthcare systems across the globe, prioritizing the limited resources was essential to minimize hospital admissions. However, despite increased demand for ocular therapeutics such as eye drops, ointment, and suspension, there was a shortage of these products as new consumers were entering the market. Manufacturers are also experiencing raised prices and potential shortages of raw ingredients due to supply restrictions. However, as the restrictions have been lifted and businesses are resuming, the demand-supply variables are coming back to normal. This will offer several growth prospects for ocular drug delivery therapeutics.
AbbVie Inc.; Bausch Health Companies Inc.; Taiwan Liposome Company, Ltd.; Ocular Therapeutix, Inc.; Graybug Vision, Inc.; Alimera Sciences, Inc.; Envisia Therapeutics; Novartis AG; EyeGate Pharmaceuticals, Inc; and Clearside Biomedical, Inc. are among the leading companies operating in the ocular drug delivery market.
Ocular Drug Delivery Market to Grow at a CAGR of 7.4% to reach US$ 27,016.20 million from 2021 to 2028
Download Free SampleOcular Drug Delivery Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Technology (Implantable Ocular Drug Delivery Systems, Particulate Drug Delivery Systems, Nano-Particle Drug Delivery System, and Others), Formulation Type (Liposomes and Nanoparticles, Solution, Emulsion, Suspension, and Ointment), Disease Type (Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Macular Degeneration, Cataract, Diabetic Macular Edema, and Others), and End User (Hospitals, Ophthalmic Clinics, and Ambulatory Surgical Centers) and Geography
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com